We optimize supplements to improve quality of life.
NL-PEPTIDES™ is a peptide synthesis technology that turns peptides into analogs.
N-acetyl peptide salt arginamide, thanks to which the peptide can be used in oral pharmaceutical compositions and stored in capsules, maintaining resistance to high temperatures and low gastric pH.
NL-BPC-157™ is a BPC-157 peptide modified into the N-acetyl BPC-157 analogue arginamide
NL-GHK-CU™ is a GHK-CU peptide modified into an N-acetyl GHK-CU analogue arginamide
NL-EPITHALON™ is an EPITHALON peptide modified into an N-acetyl Epithalon analogue arginamide
NL-PEPTIDES-DELIVERY™ peptide delivery technology via the oral route by developing a novel pharmaceutical composition containing:
The solution to the problem of bioavailability is the synthesis of new forms of peptides through the use of NL-PEPTIDES TM technology where the basic form of the peptide is transformed through modifications, into the NL-PEPTIDES form. The synthesis, through coupling with additional amino acids, modification of the N-terminal amino end and the C-terminal carboxyl end allows the peptide to increase its stability and overcome the existing gastric barrier. The greatest stability of the peptide is noted when binding to L-arginine molecules. Combination with molecules of other amino acids including lysine, ornithine and other amino acids, also found in the form of enantiomers (L-,D-) also brings the expected therapeutic effect.
Modified to the form of NL-PEPTIDES TM peptides , they remain stable under conditions of high temperature or in contact with the low pH environment found in gastric juice, which has so far been a barrier to achieving the desired effect.
The most convenient and safest method of administering therapeutic substances to the patient is oral administration. The appropriate dose of the peptide, in the innovative NL-PEPTIDES TM form, is introduced into the body by swallowing an enteral capsule, made with the patented NL-PEPTIDES-DELIVERY TM peptide delivery technology, which enters our gastrointestinal tract and, without being broken down there, migrates into the bloodstream, bringing the desired therapeutic effect. Most peptides on the market today are most often found in unmodified, basic form, which reduces their bioavailability and minimizes their effectiveness.
The next-generation peptide synthesised with NL-PEPTIDES technology is encapsulated in an enteral capsule made with NL-PEPTIDES TM DELIVERY technology.
The swallowed capsule enters the small intestine intact.
The first capsule is dissolved in the small intestine. A protease enzyme inhibitor is released - (yellow), which creates a favourable environment for the uptake of the peptide by lowering its pH to min. 5.5.
The second capsule is dissolved. The active ingredient - peptide - (blue colour) and peptide absorption enhancer acyl carnitine (green colour) are released. The peptide is absorbed into the body.
In light of scientific research, the active substance should meet certain standards. Meeting quality regulations and adequate purity of the substance allows marketing a preparation that is safe and brings confidence in the desired effect. Finding properly tested peptides that guarantee the intended effect is not easy. Tests are performed for chemical composition and microbiological purity. Any product of unknown origin may not meet the expected results.
The first three example graphs show peptide peaks from properly prepared blood samples, tested at 120min each. Successively for: NL-GHK-CU, NL-EPITHALON and NL-BPC-157 administered with our patented delivery technology.
NL-PEPTIDES-DELIVERY TM, and for regular peptides GHK-CU, EPITHALON, ARG-BPC administered in regular capsules. The next three graphs show the distribution of peptide concentrations in the test blood over a time range of 30-360min, converted to pg/ml units.
© 2022 Synthagen Laboratories. All rights reserved.